Table 2 Mutation distribution by location and grade of tumour

From: Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study

 

Poorly differentiated NEC (G3) a

Well-differentiated NETs

 
   

G2 b

G1 c

Total

Site

n/N

Type of mutation

n/N

Type of mutation

n/N

Type of mutation

(n/N)

Small intestine

1/1

TP53

2/8

CTNNB1, PIK3CA

0/9

—

3/18

Colon

8/9

KRAS, TP53, BRAF, PIK3CA, PTEN, CTNNB1, APC, RB1

0/3

—

0/1

—

8/13

Pancreas

4/4

TP53, PIK3CA, RB1, KRAS

4/10

KRAS, TP53, IDH-1, RB1

1/1

ATM

9/15

Other

7/9

PTEN, BRAF, APC, IDH1, TP53,CTNNB1, FBXW7

1/2

TP53

1/6

KRAS

9/17

Total

19/23

 

7/23

 

2/17

  
  1. Abbreviations: Other=(G1=unknown, stomach; G2=unknown, stomach; G3=unknown, breast); n=number of patients with mutations, N=total number of patients; NEC=neuroendocrine carcinoma; NET=neuroendocrine tumour.
  2. a>20 Mitoses/10 high-power fields (HPFs) or Ki67 >20%, poorly differentiated histology.
  3. b3–20 Mitoses/10 HPFs or Ki67 3–20%.
  4. c⩽2 Mitoses/10 HPFs or Ki67 ⩽2%.
Back to article page